このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

小児および若年成人の血液疾患に対する血縁または非血縁ドナーからのアルファ/ベータ T 細胞枯渇造血幹細胞移植

2026年10月28日 更新者:University of Wisconsin, Madison

TCRαβ+ および CD19+ 枯渇造血幹細胞移植は、小児および若年成人の血液疾患のための、密接に適合した非血縁ドナーまたはハプロ同一性関連ドナーからのものです。

This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha/beta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.

調査の概要

詳細な説明

This single institution, phase I clinical trial will determine the safety and feasibility of employing T-cell receptor (TCR) αβ+ and CD19+ (Cluster of Differentiation) depleted hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBMC) from closely matched unrelated donors or haploidentical donors to treat non-malignant hematologic diseases in children and young adults. Allogeneic hematopoietic stem cell transplantation has become a curative option for children and adolescents with a variety of otherwise fatal conditions. To reduce the incidence and severity of graft-versus-host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, donor grafts are depleted of T cells, either using CD34+ selection or CD3+/CD19+ depletion of grafts. However, these selection processes also deplete the graft of protective cell subsets, such as γδ T cells, natural killer (NK) cells, monocytes and dendritic cells, which play important roles in the immune response to infectious agents. Moreover, the presence of NK cells and γδ T cells in donor grafts is associated with more rapid immune reconstitution after HSCT transplantation. In order to retain these protective immune cell subsets, this trial will use a novel, highly selective graft engineering process using the Miltenyi CliniMACS system that selectively depletes αβ-T cells and B cells that are responsible for GVHD and Epstein Barr Virus (EBV)-related post-transplantation lymphoproliferative disorder, respectively. Prior to transplantation, patients will be treated with a conditioning regimen, specific for the original disorder.

The primary objective of this study is evaluation of the safety and feasibility of HSCT using TCRαβ+/CD19+ depleted hematopoietic stem cells to treat non-malignant hematologic diseases. This will be assessed by evaluating the incidence of graft failure, grade III-IV acute GVHD and chronic GVHD and TRM.

Secondary objectives include the evaluation of immune reconstitution and incidence of post-transplant infections, adverse events, serious adverse events, overall and disease-free survival and the efficiency of graft processing by the CliniMACS System.

研究の種類

介入

入学 (推定)

12

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Celeste Matsushima
  • 電話番号:608-890-8069

研究連絡先のバックアップ

研究場所

    • Wisconsin
      • Madison、Wisconsin、アメリカ、53792
        • 募集
        • American Family Children's Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3ヶ月~25年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • No Human leukocyte antigen (HLA) identical sibling available AND

  • NO HLA matched unrelated donor available OR urgent need of HSCT precludes time necessary to search for suitable HLA matched unrelated donor AND

  • Haploidentical donor OR closely matched unrelated donor available and willing to undergo mobilization and apheresis

  • If subject has genetically confirmed inherited bone marrow failure, related donor must be evaluated for this disorder and testing must be negative.

  • If subject has sickle cell disease, donor must be unaffected or have only sickle cell trait

  • Patient must be diagnosed with one of the following diseases or disorders:

    • Hemoglobinopathies

      • Sickle Cell Disease for patients ≤ 21 years of age for whom hydroxyurea has been trialed for at least six months, and failed
      • Thalassemia Major for patients ≤ 21 years of age
    • Acquired Bone Marrow Failure Syndromes

      • Paroxysmal Nocturnal Hemoglobinuria with bone marrow failure
      • Myelodysplastic Syndromes (lower risk)
      • Severe acquired aplastic anemia
    • Inherited Bone Marrow Failure Syndromes

      • Fanconi Anemia
      • Diamond Blackfan Anemia
      • Dyskeratosis Congenita and related telomere disorders
      • Congenital Thrombocytopenia Syndromes
      • Severe Congenital Neutropenia
      • Shwachman-Diamond Syndrome
    • Inborn Errors of Immunity (IEI) or Primary Immune Regulatory Disorders (PIRD)

      • Wiskott-Aldrich syndrome (WAS)
      • Chronic granulomatous disease (CGD)
      • Severe combined immunodeficiency (SCID)
      • Primary hemophagocytic lymphohistiocytosis (HLH)
  • Age ≤ 25 years (except patients with hemoglobinopathies)

  • Life Expectancy ≥ 3 months

  • Karnofsky (patients > 16 years)/Lansky (patients ≤ 16 years) index ≥ 60

  • Organ Function Requirements

    • Renal Function

      • Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) greater than or equal to 60 ml/min/1.73m^2
    • Liver Function

      • Total bilirubin < 3 mg/dL
      • Alanine aminotransferase (ALT)/ Serum glutamic-pyruvic transaminase; synonymous with ALT (SCPT) ≤ 3 x Upper Limit of Normal (ULN) for age
    • Cardiac Function

      • Ejection fraction of > 40% by Multiple gated acquisition scan (MUGA) or echocardiogram
    • Pulmonary Function

      • No evidence of dyspnea at rest
      • No supplemental oxygen requirement
      • If measured, carbon monoxide diffusion capacity (DLCO) > 50%
  • Willing to use effective birth control method if patient is of reproductive potential

  • Informed consent obtained (patient or legal representative)

Exclusion Criteria:

  • Pregnant
  • HIV infection
  • Uncontrolled, serious active infection at screening
  • Significant serious intercurrent illnesses
  • Enrollment in any other treatment study that would interfere with the endpoints of this study according to judgement of Principal Investigator (or PI designee).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment arm

Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants.

After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.

The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of grade III-IV acute graft-versus-host disease (GVHD)
時間枠:100 days post transplantation

Acute GVHD will be assessed and graded according to the Keystone Consensus Criteria for staging and grading of acute graft-versus-host disease.

100 days post transplantation
Incidence of extensive chronic GVHD
時間枠:up to 2 years

Chronic GVHD will be assessed according to the current CIBMTR (Center for International Blood and Marrow Transplant Research) manual reflecting a grading system published by Sullivan KM (Sullivan 1981).

up to 2 years
Incidence of graft failure
時間枠:up to 2 years after graft

Graft failure - defined as failure to achieve ANC > 500 /µL at Day +28 or initial neutrophil engraftment followed by a decline in ANC < 500 /µL that is unresponsive to growth factor therapy (secondary graft failure).

up to 2 years after graft
Incidence of Treatment Related Mortality (TRM)
時間枠:Day +100 post-HSCT

TRM - defined as death from any cause other than disease progression.

Day +100 post-HSCT

二次結果の測定

結果測定
メジャーの説明
時間枠
全生存期間 (OS)
時間枠:2年まで
2年まで
CliniMACS システム効率: TCRαβ+ および CD19+ 除去手順後に回収された生存 CD34+ 細胞の割合
時間枠:HSCT後12ヶ月まで
HSCT後12ヶ月まで
GVHD発生率とドナーキラー細胞免疫グロブリン様受容体(KIR)ハプロタイプ含有量との相関
時間枠:2年まで
2年まで
GVHD 発生率とドナーとレシピエント間のキラー細胞免疫グロブリン様受容体 (KIR)/KIR リガンドのミスマッチとの相関。
時間枠:2年まで
2年まで
HSC移植片の注入に関連する有害事象を起こした参加者の数
時間枠:0日目
0日目
重篤な有害事象の発生率
時間枠:2年まで
2年まで
CliniMACS system efficiency: log depletion value for CD19/CD20+ B cells after the TCRαβ+ and CD19+ depletion procedure
時間枠:Day 0
Day 0
CliniMACS system efficiency: log depletion value of TCRαβ+ T cells after the TCRαβ+ and CD19+ depletion procedure
時間枠:Day 0
Day 0
Time to neutrophil engraftment
時間枠:up to 28 days following HSCT

The time to neutrophil engraftment is defined as the post-transplant day that is the first of 3 consecutive days with an absolute neutrophil count (ANC) of >500/µL as assessed by CBC.

up to 28 days following HSCT
Time to platelet engraftment
時間枠:up to 28 days following HSCT

The time to platelet engraftment is defined as the post-transplant day that is the first of 3 consecutive days with a platelet count ≥ 20,000/µL as assessed by complete blood count (CBC), without platelet support (transfusion) for 7 days.

up to 28 days following HSCT
Percentage donor chimerism using Short Tandem Repeat (STR)
時間枠:up to 12 months following HSCT

Short tandem repeat (STR) analysis will provide the percentage donor chimerism at specific time points post-transplant.

up to 12 months following HSCT
Kinetics of lymphocyte reconstitution via immunophenotyping using flow cytometry
時間枠:up to 12 months following HSCT

Lymphocyte reconstitution will be assessed at specific time points post-HSCT, expressed as the percentage of white blood cells comprised of T, B and NK cell subsets.

up to 12 months following HSCT
CliniMACS system efficiency: number of viable blood cell subsets after the TCRαβ+ and CD19+ depletion procedure
時間枠:Day 0

Number of viable CD34+ blood stem cells, CD20+ B cells, CD3-CD56+ NK cells, TCRαβ+ T cells, and TCRγδ+ T cells in the HSC graft after the TCRαβ+ and CD19+ depletion procedure

Day 0
Event free survival
時間枠:up to 1 years

An event is defined as death, graft failure or stable mixed chimerism with disease recurrence.

up to 1 years
Incidence of symptomatic bacterial/fungal and viral reactivation requiring therapy
時間枠:up to 1 year

The incidence of infections (symptomatic bacterial/fungal and viral reactivation requiring therapy) will be used as an additional safety measure

up to 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Christian Capitini, MD、University of Wisconsin, Madison
  • スタディディレクター:Jacques Galipeau, MD、University of Wisconsin, Madison

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2029年6月1日

研究の完了 (推定)

2030年6月1日

試験登録日

最初に提出

2021年3月2日

QC基準を満たした最初の提出物

2021年3月16日

最初の投稿 (実際)

2021年3月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月29日

QC基準を満たした最後の更新が送信されました

2026年10月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2020-1251
  • A536755 (その他の識別子:UW Madison)
  • UW19113 (その他の識別子:OnCore ID)
  • 2020-1251 (その他の識別子:HS IRB UW Madison)
  • NCI-2021-02128 (レジストリ識別子:NCI CTRP)
  • Protocol Version 6 (その他の識別子:HS-IRB UW Madison)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Principal Investigator, Sponsor and funding institutions (if applicable) will ensure that all mechanisms used to share data include proper plans and safeguards to protect the rights and privacy of participants who participate in this research.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する